Cas9 from Streptococcus pyogenes is the most frequently used Cas endonuclease in CRISPR. dCas9 (deficient Cas9 or Dead Cas9) is a mutant of spCas9. It lacks the ability to cleave double-stranded DNA but is still capable of cleaving only one strand of the genome DNA (so-called “nickase”). Like Cas9, dCas9 can still be localized to the desired genome site guided by specific RNAs (gRNA), thus binding to the targeted genomic DNA sites.
This premade lentivirus express the dCa9-Null fusion under the enhanced CMV promoter (SuCMV). It does not containing any antibiotic selection. It serves as the non-specific, background control of dCas9-CRISPR based epigenomic modification (i.e express the dCas9 without a functional fusion domain.)
see details in Product Manual.
Amount: 200 ul/vial, at titer of 1×108 IFU/ml, provided in PBS solution (premixed with 10x polybrene, 60 ug/ml).